Outi Laatikainen1,2, J Miettunen3,4, S Sneck5, H Lehtiniemi3,4, O Tenhunen6,7, M Turpeinen8,3,5. 1. Research Unit of Biomedicine, University of Oulu, Oulu, Finland. outi.laatikainen@student.oulu.fi. 2. Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. outi.laatikainen@student.oulu.fi. 3. Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. 4. Center for Life Course Health Research, University of Oulu, Oulu, Finland. 5. Administration Center, Oulu University Hospital, Oulu, Finland. 6. Finnish Medicines Agency (Fimea), Helsinki, Finland. 7. Department of Oncology, Oulu University Hospital, Oulu, Finland. 8. Research Unit of Biomedicine, University of Oulu, Oulu, Finland.
Abstract
PURPOSE: Adverse drug events (ADEs) have been internationally recognized as a major threat to patient safety. The purpose of this study was to conduct a meta-analysis focusing on inpatient ADEs in the Western World to provide better estimate of the current state of medication safety in these countries. METHODS: The studies for meta-analysis were identified through electronic search in Cochrane, Scopus, Medline, and Web of science databases. Included articles focused on adult inpatient ADEs, had commonly accepted definition for ADE, and were conducted between 2000 and 2016. Disease or ADE-specific studies were excluded. Meta-analysis was conducted on the prevalence of inpatient ADEs and fatal adverse drug reactions (FADRs). RESULTS: The pooled estimate of the prevalence of inpatient ADEs was formed by 46,626 patient records included in 9 articles. Inpatient ADE prevalence was 19 and 32.3% of these ADEs were assessed preventable (MD 28.6%, SD 22.6%). Three articles including 3385 patients focused on inpatient FADRs, but the pooled estimate of this was disregarded due to low number and high heterogeneity of the included studies. CONCLUSIONS: ADEs are estimated to affect 19% of inpatients during hospitalization. Most of the ADEs are moderate in severity causing no permanent harm to the patient. Only a small amount of ADEs cause inpatient deaths, but in this meta-analysis, however, we were unable to give direct estimate of the prevalence.
PURPOSE: Adverse drug events (ADEs) have been internationally recognized as a major threat to patient safety. The purpose of this study was to conduct a meta-analysis focusing on inpatient ADEs in the Western World to provide better estimate of the current state of medication safety in these countries. METHODS: The studies for meta-analysis were identified through electronic search in Cochrane, Scopus, Medline, and Web of science databases. Included articles focused on adult inpatient ADEs, had commonly accepted definition for ADE, and were conducted between 2000 and 2016. Disease or ADE-specific studies were excluded. Meta-analysis was conducted on the prevalence of inpatient ADEs and fatal adverse drug reactions (FADRs). RESULTS: The pooled estimate of the prevalence of inpatient ADEs was formed by 46,626 patient records included in 9 articles. Inpatient ADE prevalence was 19 and 32.3% of these ADEs were assessed preventable (MD 28.6%, SD 22.6%). Three articles including 3385 patients focused on inpatient FADRs, but the pooled estimate of this was disregarded due to low number and high heterogeneity of the included studies. CONCLUSIONS: ADEs are estimated to affect 19% of inpatients during hospitalization. Most of the ADEs are moderate in severity causing no permanent harm to the patient. Only a small amount of ADEs cause inpatient deaths, but in this meta-analysis, however, we were unable to give direct estimate of the prevalence.
Entities:
Keywords:
Adverse drug events; Clinical pharmacology; Drug safety; Pharmacoepidemiology
Authors: Juan Francisco Sánchez Muñoz-Torrero; Paloma Barquilla; Raul Velasco; Maria del Carmen Fernández Capitan; Nazaret Pacheco; Lucia Vicente; Jose Luis Chicón; Sara Trejo; Jose Zamorano; Alicia Lorenzo Hernandez Journal: Eur J Clin Pharmacol Date: 2010-08-06 Impact factor: 2.953
Authors: Outi Lapatto-Reiniluoto; Laura Patinen; Mikko Niemi; Janne T Backman; Pertti J Neuvonen Journal: Basic Clin Pharmacol Toxicol Date: 2015-07-21 Impact factor: 4.080
Authors: Jeffrey M Rothschild; Klaus Mann; Carol A Keohane; Deborah H Williams; Cathy Foskett; Stanley L Rosen; Linda Flaherty; James A Chu; David W Bates Journal: Gen Hosp Psychiatry Date: 2007 Mar-Apr Impact factor: 3.238
Authors: Balthasar L Hug; Daniel J Witkowski; Colin M Sox; Carol A Keohane; Diane L Seger; Catherine Yoon; Michael E Matheny; David W Bates Journal: J Gen Intern Med Date: 2009-11-06 Impact factor: 5.128
Authors: Emma C Davies; Christopher F Green; Stephen Taylor; Paula R Williamson; David R Mottram; Munir Pirmohamed Journal: PLoS One Date: 2009-02-11 Impact factor: 3.240
Authors: Alfredo Jose Pardo-Cabello; Victoria Manzano-Gamero; Esperanza Del Pozo; Francisco Javier Gómez Jiménez; Juan de Dios Luna; Emilio Puche Cañas Journal: Intern Emerg Med Date: 2018-10-24 Impact factor: 3.397
Authors: Charlotte Arp Sørensen; Marianne Lisby; Charlotte Olesen; Ulrika Enemark; Signe Bredsgaard Sørensen; Annette de Thurah Journal: Ther Adv Drug Saf Date: 2020-05-04